Novo Nordisk Continues Growth in U.S.

Danish insulin maker Novo Nordisk is expanding its footprint in the U.S., acquiring two privately held biopharmaceutical research companies in Indiana and investing in a new manufacturing plant in North Carolina.

In picking up Calibrium and MB2, two startup firms located in Carmel, Ind., Novo Nordisk broadens its portfolio of diabetes and obesity projects and intellectual property rights, as well as its research presence in the U.S.

Financial details of the transactions were not disclosed. They are expected to close during the third quarter.

The drugmaker also announced plans to invest $1.85 billion in a facility in Clayton, N.C., where it will produce active pharmaceutical ingredients for oral semaglutide and a range of current and future GLP-1 and insulin products. — Jonathon Shacat